WO2003061681A3 - Proteins involved in the regulation of energy homeostasis and organelle metabolism - Google Patents

Proteins involved in the regulation of energy homeostasis and organelle metabolism Download PDF

Info

Publication number
WO2003061681A3
WO2003061681A3 PCT/EP2003/000738 EP0300738W WO03061681A3 WO 2003061681 A3 WO2003061681 A3 WO 2003061681A3 EP 0300738 W EP0300738 W EP 0300738W WO 03061681 A3 WO03061681 A3 WO 03061681A3
Authority
WO
WIPO (PCT)
Prior art keywords
homolog
protein
regulation
proteins involved
human
Prior art date
Application number
PCT/EP2003/000738
Other languages
French (fr)
Other versions
WO2003061681A2 (en
Inventor
Arnd Steuernagel
Andreas Molitor
Karsten Eulenberg
Guenter Broenner
Original Assignee
Develogen Ag
Arnd Steuernagel
Andreas Molitor
Karsten Eulenberg
Guenter Broenner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Develogen Ag, Arnd Steuernagel, Andreas Molitor, Karsten Eulenberg, Guenter Broenner filed Critical Develogen Ag
Priority to AU2003214048A priority Critical patent/AU2003214048A1/en
Publication of WO2003061681A2 publication Critical patent/WO2003061681A2/en
Publication of WO2003061681A3 publication Critical patent/WO2003061681A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to the use of nucleic acid and amino acid sequences of Optic atrophy 1 protein, cornichon-like, IGF-II mRNA-binding protein 3, neuralized-like, KIAA1094 protein, casein kinase (delta and epsilon), glutamate dehydrogenase, kraken homolog, sirtuin 1, escargot homolog, human KIAA1585 protein, CG11940 homolog, dappled homolog, CG11753 homolog, human KIAA0095 protein, formin-binding protein 21, and/or homologous proteins in pharmaceutical compositions, and to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis.
PCT/EP2003/000738 2002-01-25 2003-01-24 Proteins involved in the regulation of energy homeostasis and organelle metabolism WO2003061681A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003214048A AU2003214048A1 (en) 2002-01-25 2003-01-24 Proteins involved in the regulation of energy homeostasis and organelle metabolism

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
EP02001806 2002-01-25
EP02001806.5 2002-01-25
EP02003473 2002-02-14
EP02003473.2 2002-02-14
EP02004687.6 2002-02-28
EP02004687 2002-02-28
EP02009475 2002-04-25
EP02009475.1 2002-04-25
EP02013329.4 2002-06-18
EP02013329 2002-06-18
EP02029081 2002-12-30
EP02029081.3 2002-12-30

Publications (2)

Publication Number Publication Date
WO2003061681A2 WO2003061681A2 (en) 2003-07-31
WO2003061681A3 true WO2003061681A3 (en) 2004-09-23

Family

ID=27617930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/000738 WO2003061681A2 (en) 2002-01-25 2003-01-24 Proteins involved in the regulation of energy homeostasis and organelle metabolism

Country Status (2)

Country Link
AU (1) AU2003214048A1 (en)
WO (1) WO2003061681A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101407844B (en) * 2008-11-27 2011-07-27 中国农业大学 Method for detecting pig 6-7 intercostal fat thickness character and special reagent kit thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070037204A1 (en) 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
EP1652923B1 (en) * 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene overexpressed in cancer
JP2005073621A (en) * 2003-09-01 2005-03-24 Japan Science & Technology Agency Marker for cerebral tumor and method for diagnosing cerebral tumor
US20090016963A1 (en) * 2003-10-22 2009-01-15 Dalia Cohen Genes involved in neurodegenerative conditions
WO2005103240A1 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with casein kinase 1, delta, isoform 1 (csnk1d iso 1)
FR2883753B1 (en) * 2005-04-01 2008-04-11 Soc Extraction Principes Actif DERMATOLOGICAL AND / OR COSMETIC COMPOSITION CONTAINING POLYPEPTIDES
FR2900826B1 (en) 2006-05-12 2008-08-15 Soc Extraction Principes Actif USE OF PEPTIDES AS SLIMMING ACTIVE INGREDIENTS.
WO2007134818A2 (en) 2006-05-18 2007-11-29 Univ Muenchen L Maximilians Method for diagnosing mitochondrial dysfunction
KR101119417B1 (en) * 2006-11-30 2012-04-12 아크레이 가부시키가이샤 Primer set for amplification of obesity gene, reagent for amplification of obesity gene comprising the primer set, and use of the primer set
TWI627182B (en) * 2013-05-24 2018-06-21 腫瘤療法 科學股份有限公司 Imp-3 epitope peptides for th1 cells and vaccines containing the same
WO2017207733A1 (en) * 2016-06-01 2017-12-07 Universität Zürich Recombinant sirt1
CN109207523A (en) * 2017-06-29 2019-01-15 南京尧顺禹生物科技有限公司 The foundation and application of human obesity's zebra fish model based on UCP1 gene
WO2020083933A1 (en) 2018-10-23 2020-04-30 Mexav Biotech Ag Fusion polypeptides and therapeutic applications thereof
US20240011070A1 (en) * 2020-08-04 2024-01-11 712 North Inc. Methods and compositions for protease reporter assays and modulators

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002048A1 (en) * 1995-06-30 1997-01-23 Millennium Pharmaceuticals, Inc. Compositions for the treatment and diagnosis of body weight disorders, including obesity
WO1997019952A1 (en) * 1995-11-27 1997-06-05 Millennium Pharmaceuticals, Inc. The ob receptor and methods of diagnosing and treating weight
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO2001073057A1 (en) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 19053, a novel atpase-like molecule and uses thereof
WO2002000878A2 (en) * 2000-06-26 2002-01-03 Universite Paul Sabatier Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use
WO2002042455A2 (en) * 2000-11-23 2002-05-30 Develogen Ag Für Entwicklungsbiologische Forschung Modifier of organelle metalbolism

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002048A1 (en) * 1995-06-30 1997-01-23 Millennium Pharmaceuticals, Inc. Compositions for the treatment and diagnosis of body weight disorders, including obesity
WO1997019952A1 (en) * 1995-11-27 1997-06-05 Millennium Pharmaceuticals, Inc. The ob receptor and methods of diagnosing and treating weight
WO1999000123A1 (en) * 1997-06-26 1999-01-07 Pharmacia & Upjohn Ab Use of a drug capable of modulating the regulation of upc-2 and method for screening for potential drugs against obesity
WO2001073057A1 (en) * 2000-03-24 2001-10-04 Millennium Pharmaceuticals, Inc. 19053, a novel atpase-like molecule and uses thereof
WO2002000878A2 (en) * 2000-06-26 2002-01-03 Universite Paul Sabatier Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use
WO2002042455A2 (en) * 2000-11-23 2002-05-30 Develogen Ag Für Entwicklungsbiologische Forschung Modifier of organelle metalbolism

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHIESI M ET AL: "PHAMACOTHERAPY OF OBESITY: TARGETS AND PERSPECTIVES", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 22, no. 5, May 2001 (2001-05-01), pages 247 - 254, XP001080052, ISSN: 0165-6147 *
CHINNERY P F ET AL: "Mitochondria.", JOURNAL OF NEUROLOGY NEUROSURGERY & PSYCHIATRY, vol. 74, no. 9, September 2003 (2003-09-01), pages 1188 - 1199, XP008030054, ISSN: 0022-3050 (ISSN print) *
FLEURY C ET AL: "UNCOUPLING PROTEIN-2: A NOVEL GENE LINKED TO OBESITY AND HYPERINSULINEMIA", NATURE GENETICS, NEW YORK, NY, US, vol. 15, no. 3, 1 March 1997 (1997-03-01), pages 269 - 272, XP002064499, ISSN: 1061-4036 *
STUART^A^ ^B J A ET AL: "Mitochondrial proton leak and the uncoupling protein 1 homologues", BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGETICS, AMSTERDAM, NL, vol. 1504, no. 1, 1 March 2001 (2001-03-01), pages 144 - 158, XP004272947, ISSN: 0005-2728 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101407844B (en) * 2008-11-27 2011-07-27 中国农业大学 Method for detecting pig 6-7 intercostal fat thickness character and special reagent kit thereof

Also Published As

Publication number Publication date
AU2003214048A1 (en) 2003-09-02
WO2003061681A2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
WO2003061681A3 (en) Proteins involved in the regulation of energy homeostasis and organelle metabolism
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2003025121A3 (en) Igf-binding protein-derived peptide or small molecule
CA2514473A1 (en) Fused bicyclic nitrogen-containing heterocycles
WO2007120528A3 (en) Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2000047618A3 (en) HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
NO20055496L (en) Pyrazoloquinazoline derivatives, methods for their preparation and their use as kinase inhibitors
EE05191B1 (en) A pharmaceutical composition comprising tolterodine and its use
WO2005014530A3 (en) Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment of diseases
AU2003215586A1 (en) Use of folates for producing a preparation suitable for preventing and treating inflammation and diseases associated with inflammation, especially for influencing the inflammation markers crp and saa
EP1614675A3 (en) Amino acids with affinity for the alpha-2-delta protein
NO330984B1 (en) Amino acid phenoxy esters, processes for the preparation of such, intermediates in the synthetic route, pharmaceutical compositions comprising such and the use thereof for the preparation of pharmaceutical preparations for the treatment of disease
WO2006094201A3 (en) Semicarbazide-sensitive amide oxidase inhibitors
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2005002526A3 (en) Method and compositions for treatment of viral infections
KR20140012127A (en) Antagonists of the interleukin-1 receptor
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
WO2006095347A3 (en) VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS
KR20190101990A (en) Composition comprising the peptide WKDEAGKPLVK
HUP0500039A2 (en) Vaccine and method for treatment of motor neurone diseases
WO2007075572A3 (en) Orally active purine-based inhibitors of heat shock protein 90
NO331277B1 (en) Pharmaceutical composition comprising polypeptide / nucleic acid for the treatment of retinal degenerative diseases, vector, isolated polypeptide, purified antibody and use of polypeptide, nucleic acid and antibody, and methods and kits
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
WO2007134118A3 (en) Protein based composition and methods of using same
EP1571155A4 (en) Peptides and medicinal compositions containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP